▶ 国家科技部中国科技论文统计源期刊 ▶ 中国科技核心期刊 ▶ WHO西太平洋地区医学索引(WPRIM)收录期刊 ▶ 湖北优秀期刊

首页 | 编委会 | 期刊简介 | 下载专区 | 稿约 | 杂志栏目 | 当期目录 | 过刊浏览 | 专委会动态 | 药物警戒 | 学科知识 | 合理用药常识

● 最新公告

美托洛尔治疗陈旧性心肌梗死合并慢性心力衰竭的疗效和安全性

The Efficacy and Safety of Metoprolol in the Treatment of Chronic Myocardial Infarction Heart Failure

投稿时间: 2012-03-20 最后修改时间: 2012-06-15

DOI:

中文关键词: 美托洛尔 阿替洛尔 陈旧性心肌梗死 慢性心力衰竭

英文关键词:Metoprolol Atenolol Old myocardial infarction Chronic heart failure

基金项目:

作者 单位

荆门市第一人民医院药剂科 (湖北荆门 448000) 李育红

摘要点击次数:28 全文下载次数:30

中文摘要:

摘 要 目的:探讨美托洛尔治疗陈旧性心肌梗死合并慢性心力衰竭的疗效和安全性。方法:陈旧性心肌梗死合并慢性心力衰竭患者 例,随机分为治疗组与对照组各40例,治疗组给予美托洛尔治疗,对照组给予阿替洛尔治疗。2周后评价两组疗效和安全性。结果:治 有效率为 95.0% , 高于对照组的有效率 75.0% (P<0.05)。在用药后第10 min、60 min,治疗组心率较对照组下降更显著 (P<0.04) 两组死亡率、再次入院率比较,差异无统计学意义(P>0.05)。两组均未发生药品不良反应。结论: 相对于阿替洛尔,美托洛尔治疗陈旧 心肌梗死合并慢性心力衰竭能有效提高治疗疗效,降低心率,安全性好,值得推广应用。

英文摘要:

ABSTRACT Objective: To investigate the efficacy and safety of metoprolol in the treatment of chronic myocardial infarction heart failured. Methods: 80 patients with old chronic myocardial infarction heart failure were randomly divided into treatment group and controlled group 40 patients (NYHA functional classification II - III), the treatment group received metoprolol treatment, and the controlled group received atenolol treatment. Their effectiveness was defined as symptomatic relief and improvement in NYHA functional classification after tow weeks. Results: The treatment group response rate was 95.0%, which was 75.0% (P<0.05) higher than that of the controlled group. The heart rate had no significant differences 10 minutes after the treatment in both groups, but more significant difference(P< 0.05) 60 min after the treatment in the treatment group than the controlled group. The mortality and re-hospitalization were the same for both groups (P>0.05). Conclusion: The metoprolol treatment of chronic heart failure with old myocardial infarction could improve its treatment efficacy more and be safer than the atenolol treatment, and therefore, should be widely applied.

查看全文 查看/发表评论 下载PDF阅读器